Nexus Surgical and Medicare Ltd Upgraded to Sell on Technical Improvements

Quality Assessment: Weak Long-Term Fundamentals Persist

Despite the recent upgrade, Nexus Surgical’s quality metrics continue to reflect underlying weaknesses. The company’s operating profit growth remains subdued, with a compound annual growth rate (CAGR) of just 3.19% over the long term. The latest quarterly results for Q3 FY25-26 were largely flat, signalling a lack of momentum in core earnings. This stagnation is a key factor weighing on the company’s fundamental strength.

Return on equity (ROE) stands at a robust 41.7%, which on the surface suggests efficient capital utilisation. However, this high ROE is juxtaposed with a very expensive valuation, indicating that the market may be pricing in expectations that are not fully supported by earnings growth. The company’s Price to Book (P/B) ratio is 7.1, significantly above typical NBFC sector averages, underscoring the premium investors are paying for Nexus Surgical’s shares.

Valuation: Expensive Yet Discounted Relative to Peers

Nexus Surgical’s valuation remains a contentious point. While the stock trades at a discount compared to its peers’ historical averages, it is still considered expensive on absolute terms. The PEG ratio of 0.7 suggests that the stock is undervalued relative to its earnings growth, which has risen by 11% over the past year. This metric indicates some value potential, but the elevated P/B ratio tempers enthusiasm.

The stock’s current price of ₹18.01 is below its 52-week high of ₹22.00 but comfortably above the 52-week low of ₹13.26. This price range reflects a degree of volatility and investor uncertainty, particularly given the company’s mixed financial signals.

Financial Trend: Flat Performance Amid Market-Beating Returns

Financially, Nexus Surgical has delivered market-beating returns over multiple time horizons. The stock has generated a 23.36% return over the past year, outperforming the Sensex’s 6.16% gain during the same period. Over three years, the stock’s return of 75.54% far exceeds the Sensex’s 31.04%, and the five-year return of 444.11% dwarfs the benchmark’s 56.57%.

However, these impressive returns contrast with the company’s flat quarterly financial performance and modest profit growth. This divergence suggests that the stock’s price appreciation may be driven more by market sentiment and technical factors than by fundamental earnings growth.

Technical Analysis: Shift to Mildly Bullish Signals

The primary catalyst for the upgrade from Strong Sell to Sell is the improvement in technical indicators. The technical trend has moved from sideways to mildly bullish, signalling a potential positive shift in investor sentiment and price momentum.

Key technical metrics reveal a mixed but improving picture. The Moving Average Convergence Divergence (MACD) on the weekly chart is bullish, although the monthly MACD remains mildly bearish. The Relative Strength Index (RSI) shows no clear signal on both weekly and monthly timeframes, indicating a neutral momentum stance.

Bollinger Bands on both weekly and monthly charts are mildly bullish, suggesting that price volatility is stabilising with a slight upward bias. Daily moving averages are bullish, reinforcing the short-term positive momentum. The Know Sure Thing (KST) indicator is bullish on the weekly chart but mildly bearish monthly, reflecting some caution among longer-term investors.

Other technical tools such as Dow Theory show no definitive trend on weekly or monthly charts, while On-Balance Volume (OBV) data is inconclusive. Overall, the technical landscape supports a cautious optimism, justifying the rating upgrade despite fundamental concerns.

Shareholding and Market Position

Majority shareholding remains with non-institutional investors, which may contribute to the stock’s volatility and price swings. Institutional participation is limited, which often results in less stable price action and greater sensitivity to market sentiment shifts.

Despite this, Nexus Surgical’s long-term market performance has been impressive, consistently outperforming the BSE500 index over one year, three years, and even shorter periods such as three months. This track record highlights the company’s ability to generate shareholder value over time, albeit with some recent fundamental stagnation.

Conclusion: A Cautious Upgrade Reflecting Technical Optimism

The upgrade of Nexus Surgical and Medicare Ltd’s investment rating from Strong Sell to Sell reflects a nuanced balance between technical improvements and fundamental challenges. While the company’s financial performance remains flat and valuation expensive, the shift to mildly bullish technical indicators has prompted a more optimistic near-term outlook.

Investors should weigh the company’s strong long-term market returns and technical momentum against its weak earnings growth and high valuation multiples. The stock’s current Mojo Score of 37.0 and Mojo Grade of Sell indicate that caution remains warranted, but the downgrade from Strong Sell suggests that the worst may be behind the stock if technical trends continue to improve.

Given the mixed signals, Nexus Surgical may appeal to investors with a higher risk tolerance who are looking to capitalise on technical momentum, while more conservative investors might prefer to explore alternatives with stronger fundamental profiles.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today